CSIMarket
 
Xeris Biopharma Holdings Inc   (XERS)
Other Ticker:  
 
 
Price: $2.2300 $0.10 4.695%
Day's High: $2.2799 Week Perf: -0.89 %
Day's Low: $ 2.12 30 Day Perf: -30.53 %
Volume (M): 3,106 52 Wk High: $ 3.26
Volume (M$): $ 6,926 52 Wk Avg: $2.29
Open: $2.14 52 Wk Low: $1.25



 Market Capitalization (Millions $) 309
 Shares Outstanding (Millions) 138
 Employees 100
 Revenues (TTM) (Millions $) 164
 Net Income (TTM) (Millions $) 1
 Cash Flow (TTM) (Millions $) -55
 Capital Exp. (TTM) (Millions $) 0

Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc. is a US-based pharmaceutical company focused on developing and commercializing innovative, differentiated therapeutics for people with serious and life-threatening conditions. Xeris was founded in 2005 and is headquartered in Chicago, Illinois.

The company's primary focus is on the development of injectable and infusible drug formulations that are stable at room temperature, making them more convenient and accessible for patients. Their lead product, Gvoke HypoPen, is a ready-to-use, premixed, pre-measured glucagon emergency kit that treats severe hypoglycemia in adults and children with diabetes. The kit received FDA approval in August 2019 and is available for purchase in the US.

Xeris has also developed several other products under development, including a ready-to-use glucagon rescue pen for hypoglycemia associated with insulin therapy, a stable liquid glucagon for use in a healthcare setting, and an epilepsy treatment using Xeris' proprietary formulation technology.

In addition to its internal development programs, Xeris has entered into strategic partnerships and collaborations to further advance their technology and product pipeline. These partnerships include collaborations with Zealand Pharma, Intarcia Therapeutics, and Vizient, among others.

Xeris is led by a highly experienced executive team and has raised over $100 million in funding, including a successful initial public offering in 2018. The company has also been recognized for its innovation and leadership in the industry, receiving awards such as the Red Herring Top 100 North America and being named as one of FierceBiotech's Fierce 15 in 2018.

Overall, Xeris Biopharma Holdings Inc. is a rapidly growing and innovative pharmaceutical company with a strong focus on developing therapeutics that improve patient outcomes and make treatments more accessible and convenient for patients.


   Company Address: 1375 West Fulton Street Chicago 60607 IL
   Company Phone Number: 445-5704   Stock Exchange / Ticker: NASDAQ XERS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Inc Faces Intensified Losses in Fiscal Report Ending December 31, 2023

Xeris Biopharma Holdings Inc, a major pharmaceutical preparations company, recently released its financial results for the October to December 31, 2023 time-frame. Despite a decrease in the company's earnings per share, there was a significant surge in revenue, indicating positive growth for the company.
The company reported a shortfall per share of $-0.10 during the specified time-frame, compared to a shortfall of $-0.09 in the previous reporting period. Although this represents a slight increase in loss per share, it is important to note that there was substantial revenue growth during the same period. Xeris Biopharma's revenue increased by an impressive 33.931% to $44.39 million, up from $48.32 million in the previous reporting period.






 

Xeris Biopharma Holdings Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Xeris Biopharma Holdings Inc does not provide revenue guidance.

Earnings Outlook
Xeris Biopharma Holdings Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com